Adare Pharmaceuticals has acquired pharmaceutical technology company, Orbis Biosciences.
“Orbis’s customized technologies are an excellent complement to our contract development and manufacturing organization (CDMO) business which is currently focused on oral dosage forms for pharmaceutical and OTC medicines,” said John Fraher, CEO of Adare Pharmaceuticals, Inc. “In particular, their platforms create drug particles that can be dosed in oral liquid, injectable, and otic dosage forms. These will broaden our product development offerings and ultimately, advance the growth of our CDMO business, further strengthening our leadership in taste-masking and controlled-release technologies.”
Orbis provides technologies in a scaled, single-step manufacturing process. Its Precision Particle Fabrication® technology is the only technology currently on the market that can produce uniform particles in size ranges suitable for use in injectable, otic and oral dosage forms. The platform technology is flexible and customizable to accommodate a broad range of active ingredients, including small molecules, peptides, and proteins. Orbis’s proprietary technology includes three platforms: Optimμm® for oral delivery; StratμmTM for injectable delivery; and Unisun® for otic delivery.
“The acquisition by Adare will globalize the reach of our technologies and services,” said Maria Flynn, president and CEO of Orbis Biosciences. “Orbis’s focus on precision delivery solutions has enabled us to develop expertise in novel extended-release and pulsatile-release formulations and to collaborate with great partners. We are pleased to join Adare, an industry leader in drug formulation development and manufacturing.”
The acquisition was finalized on April 30th for an undisclosed amount. Orbis Biosciences will maintain its operations in Lenexa, KS and integration of the companies will commence immediately.